Neurosense Therapeutics Ltd

詳細情報 Neurosense Therapeutics Ltd 企業名

NeuroSense Therapeutics Ltd is an Israel-based clinical-stage pharmaceutical company. The Company is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The Company's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease

企業情報

企業コードNRSN

会社名Neurosense Therapeutics Ltd

上場日Dec 09, 2021

最高経営責任者「CEO」Mr. Alon Ben-Noon

従業員数15

証券種類Ordinary Share

決算期末Dec 09

本社所在地11 Hamenofim St.

都市HERZLIYA

証券取引所NASDAQ Capital Market Consolidated

国Israel

郵便番号4672562

電話番号97299531142

ウェブサイトhttps://www.neurosense-tx.com/

企業コードNRSN

上場日Dec 09, 2021

最高経営責任者「CEO」Mr. Alon Ben-Noon

役員一覧

会社名

会社名/ポジション

ポジション

株式保有

変動額

Mr. Alon Ben-Noon

Chief Executive Officer, Director

3.18M

+3.04%

Mr. Or Eisenberg

Chief Financial Officer

480.92K

+4.55%

Dr. Ferenc Tracik

Chief Medical Officer

189.62K

+54.22%

Mr. Mark W. Leuchtenberger

Independent Non-Executive Chairman of the Board

64.00K

--

Mr. Cary J. Claiborne

Non-Executive Independent Director

24.00K

--

Dr. Revital Mandil-Levin, Ph.D.

Non-Executive Independent Director

--

Ms. Christine A. Pellizzari, J.D.

Non-Executive Independent Director

--

Ms. Caren Deardorf

Non-Executive Independent Director

--

会社名

会社名/ポジション

ポジション

株式保有

変動額

Mr. Alon Ben-Noon

Chief Executive Officer, Director

3.18M

+3.04%

Mr. Or Eisenberg

Chief Financial Officer

480.92K

+4.55%

Dr. Ferenc Tracik

Chief Medical Officer

189.62K

+54.22%

Mr. Mark W. Leuchtenberger

Independent Non-Executive Chairman of the Board

64.00K

--

Mr. Cary J. Claiborne

Non-Executive Independent Director

24.00K

--

Dr. Revital Mandil-Levin, Ph.D.

Non-Executive Independent Director

--

収益内訳

データなし

データなし

事業別

地域別

データなし

株主

更新時刻: Tue, Aug 19

株主統計

種類

株主統計

比率

Ben-Noon (Alon)

12.68%

Rimon Gold Assets Ltd

9.20%

Gordon Ariel S

4.13%

Eisenberg (Or)

1.92%

Tracik (Ferenc)

0.76%

他の

71.31%

株主統計

比率

Ben-Noon (Alon)

12.68%

Rimon Gold Assets Ltd

9.20%

Gordon Ariel S

4.13%

Eisenberg (Or)

1.92%

Tracik (Ferenc)

0.76%

他の

71.31%

種類

株主統計

比率

Individual Investor

20.48%

Corporation

9.20%

Hedge Fund

0.60%

Research Firm

0.52%

Investment Advisor

0.36%

Investment Advisor/Hedge Fund

0.31%

他の

68.53%

機関投資家保有株

更新時刻: Tue, Jul 1

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q2

37

7.64M

31.03%

+143.76K

2025Q1

39

7.45M

37.28%

+353.50K

2024Q4

38

7.90M

34.02%

+1.29M

2024Q3

32

5.18M

22.45%

-1.31M

2024Q2

35

6.62M

30.57%

+1.57M

2024Q1

38

5.18M

33.20%

-953.28K

2023Q4

38

5.12M

32.81%

-1.05M

2023Q3

33

5.76M

47.99%

-945.27K

2023Q2

33

6.46M

53.11%

+1.06M

2023Q1

30

5.11M

43.34%

-185.85K

詳細を見る

株主動向

会社名

保有株式数

比率

変動額

変動率

日付

Ben-Noon (Alon)

3.18M

13.24%

+93.67K

+3.04%

Apr 07, 2025

Rimon Gold Assets Ltd

2.30M

9.6%

+2.30M

--

Dec 02, 2024

Gordon Ariel S

1.03M

4.31%

+1.30K

+0.13%

Dec 31, 2023

Eisenberg (Or)

480.92K

2%

+20.92K

+4.55%

Apr 07, 2025

Tracik (Ferenc)

189.62K

0.79%

+66.67K

+54.22%

Apr 07, 2025

Morgan Stanley & Co. LLC

50.50K

0.21%

-52.08K

-50.77%

Mar 31, 2025

Russek-Blum (Niva)

75.43K

0.31%

+10.00K

+15.28%

Apr 07, 2025

Leuchtenberger (Mark W)

64.00K

0.27%

--

Apr 07, 2025

詳細を見る

1.220USD

Neurosense Therapeutics Ltd

1.220

概要

企業名

金融

分析